Category: Vision / Eye Health

Brolucizumab Overview

Brolucizumab (INN), sold under the trade name Beovu, is a humanized single-chain antibody fragment designed for the treatment of wet age-related macular degeneration (AMD).[1][2] This drug was developed by ESBATech[3][4] (discovery to phase 2a), Alcon Laboratories (phase 2b), and Novartis (phase 3).[citation needed] Laboratory development names are RTH258 (Novartis Compound Code) and ESBA1008 (ESBATech AG). Broluc...

Read more Brolucizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Brolucizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 6mg/0.05ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Brolucizumab or a similar ingredient: (1 result)

  • BEOVU Brolucizumab-dbll

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 February 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA